This web site is designed for accessibility. Content is obtainable and functional to any browser or Internet device. This page's full visual experience is available in a graphical browser that supports web standards. See reasons to upgrade your browser.

Suresh Srivastava

Scientist


Telephone:  (631) 344-4459
e-mail: suresh@bnl.gov

Research Interests

  • Novel radionuclide and radiopharmaceuticals for oncologic imaging and therapy
  • Molecular contructors for gene/radioisotopic therapy
  • Suresh Srivastava’s interests are the development, testing, and clinical trials of:
    1) Sn-117m chelates for treatment of bone pain, primary/ metastatic bone cancer, and rheumatoid arthritis; and 2) Anti-angiogenic peptides, metalloproteinase inhibitors, and STTR-binding peptides, labeled with no-carrier-added Sc-47, Sn-117m, Hg-195m, and other radioisotopes, for tumor therapy. In addition, he is interested in the development of radiolabeled recombinant fusion proteins, scFv antibodies, and viral vectors as vehicles for therapy of cancer.

 Education & Concurrent Positions

  • B.S., Agra University, 1955
  • M.S., Agra University, 1957
  • Ph.D., University of Allahabad, 1961
  • Head, Radionuclide and Radiopharmaceutical Program, Medical Dept., BNL, 1983-Present
  • Adjunct Professor of Radiology, State Univ. of New York, Stony Brook, ????

Selected Publications

  • Srivastava S.
    The Role of electron-emitting radiopharmaceuticals in the palliative treatment of metastic bone pain and for radiosynovectomy: applications of conversion electron emitter Tin-117m.
    Brazilian Archives of Biology and Technology, 50(Special Number):49-62 (2007).
  • DeNardo S.J., DeNardo G.L., Kukis D.L., Shen S., Kroger L.A., DeNardo D.A., Goldstein D.S., Mirick G.R., Salako Q., Mausner L.F., Srivastava S.C. and Meares C.F.
    67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.
    J. Nucl. Med., 40(2):302-310 (1999).  PubMed
  • Srivastava S.C., Atkins H.L., Krishnamurthy G.T., Zanzi I., Silberstein E., Meinken G., Swailem F., Mausner L.F., D'Alessandro T., Cabahug C.J., Lau Y., Park T. and Madajewicz S.
    Treatment of metastatic bone pain with tin-117m stannic DTPA: A phase I/II clinical study.
    Clinical Cancer Res., 4(1):61-68 (1998).  PubMed
  • Krishnamurthy G., Swailem F., Srivastava S.C., Atkins H.L., Simpson L.J., Walsh T.K., Ahmann F.R., Meinken G.E. and Shah J.
    Tin-117m(4+)DTPA: Pharmacokinetics and imaging characteristics in patients with metastatic bone pain.
    J. Nucl. Med., 38(2):230-237 (1997).  PubMed
  • Srivastava S.C.
    Is there life after technetium: What is the potential of developing new broad-based radionuclides.
    Semin. Nucl. Med., 26(2):119-131 (1996).  PubMed
  • Srivastava S.C.
    Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy.
    Cancer Biother. Radiopharm., 11(1):43-50 (1996).  PubMed
  • Srivastava S.C., Mausner L.F., Mease R.C., Meinken G.E., Joshi V, Kolsky K., Sweet M. and Steplewski Z.
    Development and evaluation of 67Cu and 153Sm labeled conjugates for tumor radioimmunotherapy.
    Int. J. Pharmcognosy, 33: 92-101 (1995).

Top of Page

Last Modified: April 25, 2012
Please forward all questions about this site to: Nicholas J. Franco